Deal Watch: Sanofi Offloads Established Products, Lilly Testing 3D-Printed Drugs
Specialty pharma Neuraxpharm is taking on 38 mature brands from Sanofi, in CNS, pain and vascular diseases. Lilly is working with Triastek on 3D printing technology for targeted release of drugs in specific regions of the gastrointestinal tract.
You may also be interested in...
Aspect says its bioprinted tissue therapeutics include immune-resistant encapsulation, which Novo Nordisk hopes will offer a safer approach to type 1 diabetes cell therapy.
After failure to close of a potential $177m buyout by EW Pharma, TherapeuticsMD will resolve its debt by selling its three-product women’s health portfolio to Mayne.
Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.